Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

Moderna is investing more than $140 million to bring drug manufacturing to its Massachusetts campus, a move that it says will ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network ...

Mixed options sentiment in Moderna (MRNA), with shares down 94c near $23.98. Options volume relatively light with 49k contracts traded and calls ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Moderna will invest $140 million in expanding its U.S. manufacturing capacity and onshoring its drug manufacturing to its existing facility in Norwood, Mass. The company said it will now operate full ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Piper Sandler's 37 th Annual Healthcare Conference, on Tuesday, December 2 nd at 11:00am ET A live webcast of each of the presentation will be available under "Events and Presentations" in the ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...